After an analysis that indicates some epilepsy treatments may increase the risk of suicidal behavior, the Food and Drug Administration held a closed meeting Monday with drug manufacturers to discuss adding a warning label to such medications. Some drug officials said the research might be flawed because it combines findings about 11 available epilepsy drugs, which are not necessarily alike.

Related Summaries